Naslov
Farmakoterapija šećerne bolesti tipa 2

Autori
Cvek, Josipa ; Mirošević Skvrce, Nikica ; Vučić, Katarina ; Andrić, Adriana ; Ortner Hadžiabdić, Maja

Izvornik
Farmaceutski glasnik : glasilo Hrvatskog farmaceutskog društva (0014-8202) 75 (2019), 9; 629-664

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Diabetes mellitus, type 2, therapy

Sažetak
Although normoglycemia for most diabetic patients is hard to achieve, any therapy that contributes to glucose regulation may delay the development of complications and improve the quality of life for the patients. While therapy of type 1 diabetes is primarily focused on maintaining good glycemic control, in patients with type 2 diabetes attention should also be paid to the treatment of comorbidities. Polypharmacy in type 2 diabetes increases the risk of adverse drug reactions (ADRs) and negatively affects patient adherence. In order to attain optimal treatment outcomes, an individualized approach with awareness of possible ADRs should be applied in the pharmaco therapy of diabetic patients. The risks of long- term use of new antidiabetics are not fully clarified and spontaneous reporting of their suspected ADRs resulted in a series of safety signals in post- approval phase. This paper reviewed the available literature on the pharmacotherapeutic options for the treatment of type 2 diabetes and lists current knowledge on the safety profile of antidiabetic drugs.

Izvorni jezik
Hrvatski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA